Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech firm, has secured an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This deal grants Clearmind global rights to develop, manufacture, and commercialize novel psychedelic-derived compounds aimed at treating PTSD and other mental health conditions. The potential PTSD treatment market is estimated to grow from $16.8 billion in 2023 to $27.37 billion by 2033. Current treatments for PTSD, such as SSRIs and SNRIs, often show efficacy and side effects like nausea and insomnia. Clearmind's agreement includes milestone payments, royalties, and IP protection commitments.
- Clearmind Medicine secures exclusive global rights to develop, manufacture, and commercialize innovative psychedelic compounds for PTSD treatment.
- The global market for PTSD treatment is expected to grow from $16.8 billion in 2023 to $27.37 billion by 2033.
- Agreement includes milestone payments, royalties on future sales, and intellectual property protection commitments.
- Current PTSD treatments like SSRIs and SNRIs offer efficacy and have side effects including nausea, weight gain, and insomnia.
- Clearmind is responsible for the ongoing development and adherence to regulatory guidelines, which can be resource-intensive.
Insights
Clearmind Medicine's exclusive licensing agreement with Yissum Research Development Company positions it uniquely within the evolving landscape of psychedelic-derived therapeutics. By securing global rights to novel compounds aimed at treating PTSD and other mental health disorders, Clearmind potentially sets itself apart in a market characterized by highly competitive yet often ineffective traditional treatments like SSRIs and SNRIs.
The global market for PTSD treatment is projected to grow substantially from
The partnership with a reputable institution like the Hebrew University adds credibility, but it's important to monitor the terms of milestone payments and royalties as these financial obligations could impact Clearmind’s cash flow and profitability in the long term. Additionally, the commitment to safeguarding intellectual property will be important in maintaining competitive advantage.
The recent licensing agreement could mark a strategic shift for Clearmind Medicine, potentially expanding its revenue streams through the development and commercialization of new PTSD treatments. However, investors should be cautious of the milestone payments and royalties detailed in the agreement. These future financial obligations might strain the company's financial stability if the commercialization process faces delays or setbacks.
Retail investors should also consider that the biotechnology sector is inherently risky, particularly for clinical-stage companies like Clearmind. The potential for high returns exists, but it comes with substantial risk given the uncertainties surrounding clinical trial outcomes and regulatory approvals.
The PTSD treatment market's projected growth from
However, market entry strategies will be key. Clearmind must ensure robust marketing and distribution plans to compete effectively against established players in the PTSD treatment market. Additionally, regulatory approval timelines and market acceptance rates will be pivotal in determining the success of this new venture.
Vancouver, Canada, June 20, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, recently announced that it signed an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement provides Clearmind with exclusive global rights to further develop, manufacture, and commercialize innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa and Avi Priel from the Hebrew University. These novel compounds are targeted at treating post-traumatic stress disorder (PTSD) and other mental health conditions.
The global market for PTSD treatment, valued at
Under the terms of the agreement, Clearmind receives exclusive rights to develop, manufacture, and commercialize novel compounds for treating PTSD and other mental health disorders. Clearmind is responsible for the ongoing development and potential commercialization in line with regulatory guidelines.The agreement includes future milestone payments, royalties on future sales, and commitments to safeguard intellectual property rights.
About Yissum
Yissum is the technology transfer company of the Hebrew University of Jerusalem. Founded in 1964, Yissum serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum’s mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. The company has registered more than 11,680 patents globally, licensed over 1,160 technologies, and has spun out over 260 companies. Yissum’s business partners span the globe. For further information please visit www.yissum.co.il.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of eighteen patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected growth of the global market for PTSD treatment. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the recent licensing agreement involving Clearmind Medicine (CMND)?
How large is the market for PTSD treatment?
What are the current treatment options for PTSD mentioned in the press release?
What are the financial terms included in Clearmind Medicine's licensing agreement?
